You certainly have a lot to be proud of. Your family must be so very proud of what you have become.
Yes, absolutely. I do not like all of Judge Navarro's claims constructions necessarily and actually prefer the claims constructions by the Delaware U.S. District Court in SPPI's Fusilev infringement suit against InnoPharma. The Delaware Court went across the Board in favor of SPPI's proposed interpretations, but that trial is following the Nevada case which is now over. Post-trial briefs are due Feb. 13th and a post-trial conference is now scheduled for March 5th in the event the parties can still settle. Otherwise, Judge Navarro will rule shortly thereafter.
I disagree. This is neither positive or negative for SPPI.
I think the Supreme Court has merely stated that the factual findings at the U.S. District Court level are not to be redetermined "de novo" or all over again by the U.S. Federal Circuit Court of Appeals which hears all IP cases appealed from U.S. District Courts anywhere in the U.S.
In other words, whatever Judge Gloria Navarro's claims construction findings are regarding the meaning of certain terms in the Fusilev patent, then upon any appeal by either party such interpretations may NOT be overturned without clear and convincing evidence and are not to be redetermined from the beginning.
Thank you for your due diligence. If it is that big of a revenue producer, SPPI will simply buyout CASI.
Not for this - LOL. You could not afford it.
Pretty good list and does not even contemplate SPI-2012 or APAZ or CE Melph which are much, much bigger.
If you cannot see beyond everyone else's narrow-minded horizons, then you never reach for opportunity nor do you achieve 10 to 20 baggers instead of 5 baggers. It is all there in front of you.
If SPPI delivers on ANY combination of the above and/or Apaz. It is less than 36-months until 2018. Just over the hill.
If you don't like PE Ratios, use Book Value in 2018. AMGEN is 5 to 7 Times Book Value. What is 5 to 7 Times 2018 Book Value?
SPPI would be $20 to $28 PPS today alone based on AMGEN's multiples. What about 2018?
Assuming that (i) the Fusilev patent is upheld much less the Orphan Drug status , (ii) CE Melphalan is approved later this year, and SPI-2012 data does indicate that it is at a minimum bioequivalent status, it would seem reasonable that by 2018 or so:
$200 to $250 million - Existing 5 drugs
$100 million - CE Melph
$600 million - SPI - 2012
$900 million TOTAL/Annually
With 64.5 million shares outstanding and a $200 million existing annual burn rate plus up to another $100 million for other pipeline expansion costs, SPPI could have about $9 per share in pre-tax earnings per share.
What is the PE Ratio? Any guesses? AMGEN is 25.
Please, just Stop! You are embarrassing yourself and your family.
Actually, all Three Analysts other than Jeffries are ALL at $15 PPS target. Jeffries at $8 is the only one less than $15 PPS.
On or before early March, SPPI should:
1. Obtain favorable ruling or settlement on the Fusilev trial in Nevada;
2. Obtain Maida and Kassner's immediate resignations;
3. Announce SPI-2012 Phase II data;
4. Announce APAZ NDA strategy;
5. Start Phase III for SPI-2012;
6. Enter into Co-Marketing Agreement for SPI-2012 in Europe with Big Pharma; and
7. Announce the immediate Buyback of Ten Percent of the Outstanding Shares based on the Board's determination that the Company is severely undervalued.
All in "one fail swoop". Done.
1. Q4 estimate (-0.14). Not sure how Topo's $25 million is to be accounted for.
2. No, new BV will not be below $3.50 PPS.
Most importantly, BV is not that important for Biotechs in my view. What is Microsoft's BV. AMGEN is FIVE TIMES BV and Estimates are SEVEN TIMES BV. IF the same, SPPI would be $18 to $28 PPS.
Those are GAAP based financial losses. SPPI is effectively cash flow breakeven from operations excluding one-time payments like Topo's $25 Million.
That is why SPPI still had over $140 million in cash and equivalents at the end of Q3 2014. The non-GAAP Financials are the key from a cash burn standpoint as they do not include non-cash expenses like option vesting, amortization, depreciation etc.
That is excellent, but I would suggest slowing down a little bit. 16 lbs is a lot in that short period especially since you were only 224 lbs. to start. If you get to 180 lbs, by year-end 2015 that is great.
"stocks.toshort stocks.toshort • Jan 2, 2015 4:55 PM Flag1 users liked this posts users disliked this posts 6 Reply Caveman
If I'm NOT an owner of SPPI LONG shares and it truly doubles, I'll be one of the first to congratulate all long-time holders, including pump dudes. I'll even look back on the $6s 'opportunity' with regret.
For 2015, as one of my 15 New Year's resolutions -
I intend to REDUCE my SPPI message board posting QUANTITY.
You are welcome!"
Yes, I agree. Just jerking cigan's chain.
Incorrect again. SPPI owns 16.66% of CASI. 20% pre-transaction and 16.66% post-transaction today. Zevalin $ go to CASI not SPPI. There is no revenue to SPPI from Zevalin sales in Hong Kong or anywhere else in China.